unknown
Stage
About
Abscint develops advanced in vivo molecular imaging diagnostics using anti-HER2 PET tracers for precision diagnostics and monitoring of HER2-positive cancers such as breast cancer.
Explore Abscint's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.